natgillin/translations-raw huggingface dataset:
Halimatoz is only available as 40 mg pre-filled syringe / pre-filled pen.
Zdravilo Halimatoz je na voljo samo v 40 mg napolnjeni injekcijski brizgi/napolnjenem injekcijskem peresniku.
Carriers of HBV who require treatment with Halimatoz should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.
Pri bolnikih, ki so pozitivni na okužbo s hepatitisom B, se priporoča posvetovanje z zdravnikom specialistom za zdravljenje okužb s hepatitisom B. Nosilce HBV, ki potrebujejo zdravljenje z zdravilom Halimatoz, je treba ves čas zdravljenja in več mesecev po koncu zdravljenja natančno spremljati glede znakov in simptomov aktivne okužbe s HBV. O zdravljenju nosilcev HBV s protivirusno terapijo v kombinaciji z antagonistom TNF za preprečitev reaktivacije HBV ni zadostnih podatkov.
The recommended dose of Halimatoz for patients with enthesitis-related arthritis from 6 years of age is based on body weight (table 2).
Priporočeni odmerek zdravila Halimatoz pri bolnikih z artritisom, povezanim z entezitisom, starih 6 let in več, temelji na telesni masi (preglednica 2).
Your healthcare provider should show you how to prepare and inject Halimatoz properly using the prefilled syringe before you use it for the first time.
Preden zdravilo Halimatoz prvič uporabite, vam mora zdravstveni delavec pokazati, kako ga pravilno pripraviti in injicirati z napolnjeno injekcijsko brizgo.
Halimatoz is supplied in a single-use clear type I glass syringe with a stainless steel needle with a needle guard with finger flange, rubber needle cap and plastic plunger rod, containing 0.8 ml of solution.
Zdravilo Halimatoz je na voljo v injekcijski brizgi za enkratno uporabo iz prozornega stekla tipa I z iglo iz nerjavečega jekla s ščitnikom za iglo z držalom, z gumijastim pokrovčkom za iglo in s plastičnim batom, ki vsebuje 0,8 ml raztopine.
Halimatoz 40 mg solution for injection in pre-filled syringe adalimumab
Halimatoz 40 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku adalimumab
In monotherapy, some patients who experience a decrease in their response to Halimatoz 40 mg every other week may benefit from an increase in dosage to 40 mg adalimumab every week or 80 mg every other week.
Med monoterapijo lahko nekaterim bolnikom, ki se jim zmanjša odziv na zdravilo Halimatoz 40 mg vsak drugi teden, koristi povečanje odmerka adalimumaba na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Halimatoz should be used with caution in patients with mild heart failure (NYHA class I/II).
Pri bolnikih z blagim srčnim popuščanjem (razred I/II po NYHA) je treba zdravilo Halimatoz uporabljati previdno.
Some patients who experience decrease in their response to Halimatoz 40 mg every other week may benefit from an increase in dosage to 40 mg Halimatoz every week or 80 mg every other week.
Nekaterim bolnikom, ki se jim zmanjša odziv na zdravilo Halimatoz 40 mg vsak drugi teden, lahko koristi povečanje odmerka zdravila Halimatoz na 40 mg vsak teden ali na 80 mg vsak drugi teden.
Halimatoz 40 mg solution for injection (injection) in pre-filled syringe is supplied as a 0.8 ml clear to slightly opalescent, colourless to slightly yellowish solution.
Zdravilo Halimatoz 40 mg raztopina za injiciranje (injekcija) v napolnjeni injekcijski brizgi je na voljo kot bistra do rahlo opalescentna, brezbarvna do rahlo rumenkasta raztopina.
Halimatoz is available as a pre-filled syringe and a pre-filled pen (SensoReady).
Zdravilo Halimatoz je lahko na voljo v napolnjeni injekcijski brizgi in napolnjenem injekcijskem peresniku (SensoReady).
The recommended dose of Halimatoz for adult patients with uveitis is an initial dose of 80 mg, followed by 40 mg given every other week starting one week after the initial dose.
Priporočeni začetni odmerek zdravila Halimatoz za odrasle bolnike z uveitisom je 80 mg, čemur sledi 40 mg odmerek vsak drugi teden, ki se ga začne dajati en teden po začetnem odmerku.
Halimatoz 40 mg solution for injection (injection) in pre-filled pen is supplied as a 0.8 ml clear to slightly opalescent, colourless to slightly yellowish solution.
Zdravilo Halimatoz 40 mg raztopina za injiciranje (injekcija) v napolnjenem injekcijskem peresniku je na voljo kot bistra do rahlo opalescentna, brezbarvna do rahlo rumenkasta raztopina.
Halimatoz 40 mg solution for injection in single-use pre-filled SensoReady pen Halimatoz is supplied in a single-use pre-filled syringe assembled into a triangular-shaped pen with transparent window and label (SensoReady).
Zdravilo Halimatoz je na voljo v napolnjeni injekcijski brizgi za enkratno uporabo, v peresniku trikotne oblike s prozornim okencem in oznako (peresnik SensoReady®).
The recommended dose of Halimatoz for adult patients is an initial dose of 80 mg administered subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after the initial dose.
Priporočeno odmerjanje zdravila Halimatoz za odrasle bolnike je začetni odmerek 80 mg subkutano in nato 40 mg subkutano vsak drugi teden, začenši en teden po začetnem odmerku.
Discontinuation of Halimatoz therapy should be considered in patients with confirmed significant haematologic abnormalities.
Pri bolnikih s potrjenimi pomembnimi hematološkimi nepravilnostmi je treba razmisliti o prekinitvi terapije z zdravilom Halimatoz.
Halimatoz is administered via subcutaneous injection.
Zdravilo Halimatoz se odmerja v obliki subkutane injekcije.
The syringe inside the pen is made of type I glass with a stainless steel needle, an inner rubber needle cap, and a rubber stopper, containing 0.8 ml solution.
Brizga v peresniku je narejena iz prozornega stekla tipa I z iglo iz nerjavečegaa jekla, notranjim gumijastim pokrovčkom za iglo in gumijasto zaporko, ki vsebuje 0,8 ml raztopine.
Halimatoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).
Zdravilo Halimatoz je indicirano za zdravljenje aktivnega artritisa, povezanega z entezitisom pri bolnikih, starih 6 let in več, ki so se neustrezno odzvali ali so intolerantni za običajno zdravljenje
The recommended dose of Halimatoz is an initial dose of 80 mg (as two 40 mg injections in one day), followed by 40 mg every other week starting one week later.
Priporočeno odmerjanje zdravila Halimatoz je začetni odmerek 80 mg (kot dve 40 mg injekciji v enem dnevu), čemur sledi 40 mg vsaka dva tedna z začetkom en teden po začetnem odmerku.
The recommended Halimatoz induction dose regimen for adult patients with moderate to severe ulcerative colitis is 160 mg at week 0 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days) and 80 mg at week 2 (given as two 40 mg injections in one day).
Priporočena shema odmerjanja zdravila Halimatoz med indukcijo je pri odraslih bolnikih z zmerno do hudo aktivnim ulceroznim kolitisom 160 mg 0. teden (aplicirano kot štiri 40 mg injekcije v enem dnevu ali kot dve 40 mg injekciji na dan dva dni zapored) in 80 mg 2. teden (aplicirano kot dve 40 mg injekciji v enem dnevu).
The usual Halimatoz dose for adults with ulcerative colitis is 160 mg initially (as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), then 80 mg (as two 40 mg injections) two weeks later, and then 40 mg every other week.
Običajni začetni odmerek zdravila Halimatoz pri odraslih z ulceroznim kolitisom je 160 mg (kot štiri 40 mg injekcije v enem dnevu ali po dve 40 mg injekciji na dan dva zaporedna dneva), nato 80 mg (kot dve 40 mg injekciji) dva tedna pozneje in nato 40 mg vsaka dva tedna.
The recommended Halimatoz dose regimen for adult patients with hidradenitis suppurativa (HS) is 160 mg initially at Day 1 (given as four 40 mg injections in one day or as two 40 mg injections per day for two consecutive days), followed by 80 mg two weeks later at Day 15 (given as two 40 mg injections in one day).
Priporočena shema odmerjanja zdravila Halimatoz pri odraslih bolnikih s hidradenitis suppurativa (HS) je 160 mg na 1. dan (apliciranov obliki štirih 40 mg injiciranj na dan ali z dvema 40 mg injiciranjema na dan dva dni zapored), ki mu sledi 80 mg dva tedna kasneje na 15. dan (apliciranov obliki dveh 40 mg injiciranj v enem dnevu).
The syringe inside the pen is made of type I glass with a stainless steel needle and an inner rubber needle cap, containing 0.8 ml of solution.
Injekcijska brizga v peresniku je narejena iz prozornega stekla tipa I z iglo iz nerjavečega jekla in notranjim gumijastim pokrovčkom za iglo ter vsebuje 0,8 ml raztopine.
Halimatoz dose for paediatric patients with uveitis Patient weight
Odmerjanje zdravila Halimatoz pri pediatričnih bolnikih z uveitisom
Your Halimatoz single-use pre-filled SensoReady pen
Vaš napolnjeni injekcijski peresnik SensoReady zdravila Halimatoz za enkratno uporabo
Vertigo and visual impairment may occur following administration of Halimatoz (see section 4.8).
Po dajanju zdravila Halimatoz se lahko pojavita vrtoglavica in poslabšanje vida (glejte poglavje 4.8).
Halimatoz is contraindicated in moderate to severe heart failure (see section 4.3).
Pri bolnikih z zmernim ali hudim srčnim popuščanjem je zdravilo Halimatoz kontraindicirano (glejte poglavje 4.3).
Halimatoz can reduce the number of nodules and abscesses you have, and the pain that is often associated with the disease.
Zdravilo Halimatoz lahko zmanjša število vozličev in ognojkov, ki jih imate.
Halimatoz therapy should not be continued in patients failing to respond within this time period.
Pri bolnikih, ki se v tem času ne odzovejo, zdravljenja z zdravilom Halimatoz ni priporočljivo nadaljevati.
• You might get infections more easily while you are receiving Halimatoz treatment.
• Med zdravljenjem z zdravilom Halimatoz se lahko poveča dovzetnost za okužbe.
Patients should be instructed to seek medical advice if signs / symptoms suggestive of a tuberculosis infection (e.g., persistent cough, wasting/weight loss, low grade fever, listlessness) occur during or after therapy with Halimatoz.
Halimatoz ali po njem doživijo znake ali simptome, ki nakazujejo tuberkulozno okužbo (npr. trdovraten kašelj, hujšanje/izgubljanje teže, nekoliko zvišano telesno temperaturo).
Children and adolescents from 4 to 17 years of age weighing 30 kg or more The recommended dose of Halimatoz is an initial dose of 40 mg, followed by 40 mg one week later.
Otroci in mladostniki, starejši od 2 let, ki tehtajo 30 kg ali več Običajni odmerek zdravila Halimatoz je 40 mg vsak drugi teden z metotreksatom.
Room spinning sensation (vertigo) and vision disturbances may occur after taking Halimatoz.
Po dajanju zdravila Halimatoz se lahko pojavita vrtoglavica (občutek vrtenja prostora) in poslabšanje vida.
Treatment with Halimatoz must be discontinued in patients who develop new or worsening symptoms of congestive heart failure.
Pri bolnikih, ki se jim na novo pojavijo simptomi kongestivnega srčnega popuščanja ali se jim takšni simptomi poslabšajo, je treba zdravljenje z zdravilom Halimatoz prekiniti.
Children and adolescents from 6 to 17 years of age weighing 40 kg or more
Otroci in mladostniki z luskavico v plakih Otroci in mladostniki, stari od 4 do 17 let, ki tehtajo 30 kg ali več
The usual dose regimen is 80 mg (as two 40 mg injections in one day) initially followed by 40 mg two weeks later.
Običajna shema odmerjanja pri Crohnovi bolezni je 80 mg (kot dve 40 mg injekciji v enem dnevu) na začetku, čemur sledi 40 mg vsak drugi teden dva tedna kasneje.
Halimatoz 40 mg solution for injection in pre-filled syringe:
Halimatoz 40 mg raztopina za injiciranje v napolnjeni injekcijski brizgi adalimumab
(see also section 5.1.)
(Glejte tudi poglavje 5.1.)
Long-term safety evaluations are ongoing.
Dolgoročno vrednotenje varnosti še poteka.
Date of first authorisation: 22 May 2014 Date of latest renewal: 12 December 2018
Datum prve odobritve: 22. maj 2014 Datum zadnjega podaljšanja: 12. december 2018
The reasons for this are not fully known and are possibly related to the mechanism of action.
Razlogi za to niso povsem pojasnjeni, lahko pa bi bili povezani z mehanizmom delovanja.
There is insufficient information on what effect this may have on your baby.
Ni dovolj podatkov o tem, kako to vpliva na vašega otroka.
The Physican's Educational Material should contain the following key messages:
Izobraževalno gradivo za zdravnike mora vsebovati naslednja ključna sporočila:
• if you are going to receive any vaccination or have recently had a vaccination.
• če boste prejeli katero koli cepivo ali ste pred kratkim bili cepljeni.
Entyvio is not recommended for use in children or adolescents (under 18 years of age) due to the lack of information regarding the use of this medicine in this age group.
Uporaba zdravila Entyvio pri otrocih in mladostnikih (mlajših od 18 let) ni priporočljiva zaradi pomanjkanja podatkov o uporabi tega zdravila pri tej starostni skupini.
If not fully dissolved after 20 minutes, allow another 10 minutes for dissolution.
Če se vsebina po 20 minutah popolnoma ne raztopi, počakajte še nadaljnjih 10 minut.
• if you have cancer, tell your doctor.
• če imate raka, o tem obvestite svojega zdravnika.
Gently swirl the vial for at least 15 seconds.
Vialo vsaj 15 sekund nežno vrtite.
Reconstituted and diluted solutions: Use immediately.
Rekonstituirana in razredčene raztopine: uporabite takoj.
Every 8 weeks
Vsakih 8 tednov
Exploratory analyses provide additional data on key subpopulations studied.
Eksplorativne analize so dale dodatne podatke o ključnih preiskanih podpopulacijah.
Some infections may become serious and possibly even life-threatening if left untreated.
Nekatere okužbe lahko postanejo resne in lahko celo ogrozijo življenje, če se jih ne zdravi.
If you feel dizzy, do not drive or use tools or machines.
Če ste omotični, ne smete upravljati vozil, orodji ali strojev.
• Your doctor will also give you a Patient Alert Card for you to keep with you at all times.
• Zdravnik vam bo dal tudi opozorilno kartico, ki jo imejte ves čas pri sebi.
• if you are allergic to vedolizumab or any of the other ingredients of this medicine (listed in section 6).
• če ste alergični na vedolizumab ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
What Entyvio is and what it is used for
Kaj je zdravilo Entyvio in za kaj ga uporabljamo
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Pred začetkom uporabe zdravila natančno preberite navodilo, ker vsebuje za vas pomembne podatke !
Administration of the influenza vaccine should be by injection in line with routine clinical practice.
Cepiva proti gripi je treba injicirati v skladu z rutinsko klinično prakso.
If you have Crohn's disease you will first be given other medicines.
Če imate Crohnovo bolezen, se boste najprej zdravili z drugimi zdravili.
Live and oral vaccines
Živa in peroralna cepiva
The exact elimination route of vedolizumab is not known.
Natančna pot izločanja vedolizumaba ni znana.
Timing of treatment (infusion)
Čas zdravljenja (infuzije)
These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML).
Vse to so lahko simptomi resne in potencialno smrtne možganske bolezni, imenovane progresivna multifokalna levkoencefalopatija (PML).
The safety and efficacy of vedolizumab in children aged 0 to 17 years old have not been established.
Pediatrična populacija Varnost in učinkovitost vedolizumaba pri otrocih, starih od 0 do 17 let, nista bili dokazani.
Most infusion related reactions occurred within the first 2 hours.
Večina reakcij, povezanih z infundiranjem, se je pojavila v prvih 2 urah.
For more detailed information, see infusion and allergic reactions in section 4.
Za podrobnejše informacije glejte infuzijske in alergijske reakcije v poglavju 4.
The treatment interruption period in clinical trials extended up to one year.
V kliničnih preskušanjih so obdobja prekinitve zdravljenja trajala do enega leta.
Tell your doctor or nurse immediately when you first receive this medicine, during treatment, and between doses:
Nemudoma obvestite zdravnika ali medicinsko sestro; preden boste prvič prejeli to zdravilo, med zdravljenjem ali med posameznimi odmerki:
• night sweats
• nočno znojenje,
What you need to know before you are given Entyvio
Kaj morate vedeti, preden boste prejeli zdravilo Entyvio
¶Durable clinical remission: Clinical remission at ≥ 80% of study visits including final visit (week 52)
¶ Trajna klinična remisija: klinična remisija pri ≥ 80 % študijskih obiskov, vključno s finalnim obiskom
• Consider the patient's full medical history, including any prior or concurrent biological medicine use
• Skrbno je treba preučiti celotno anamnezo bolnika, vključno s kakršno koli predhodno ali sočasno uporabo bioloških zdravil.
These could occur during or after the infusion.
Ti znaki se lahko pojavijo med ali po infundiranju zdravila.
If you have ulcerative colitis, you will first be given other medicines.
Če imate ulcerozni kolitis, se boste najprej zdravili z drugimi zdravili.
Other live vaccines may be administered concurrently with vedolizumab only if the benefits clearly outweigh the risks.
Druga živa cepiva se sočasno z vedolizumabom lahko uporablja le, če koristi cepljenja jasno prevladajo nad tveganji.
You must not be given Entyvio:
Zdravila Entyvio ne smete prejeti:
Over time, there was no significant increase in the rate of serious infections.
Delež resnih okužb se s časom ni pomembneje povečal.
Do not vigorously shake or invert.
Viale ne smete močno stresati ali obračati.
*p < 0.0001 †p ≤ 0.001 ‡p < 0.05
† p < 0,001 ‡ p < 0,05
Among these patients,
Bolniki,
Do not hold1
Ne shranjujte1
Efficacy Results for GEMINI II at week 52 Placebo n = 153*
Rezultati učinkovitosti v 52. tednu v študiji GEMINI II Placebo n = 153*
Overall, results from the clinical program to date do not suggest an increased risk for malignancy with vedolizumab treatment; however, the number of malignancies was small and long-term exposure was limited.
Na splošno rezultati kliničnega programa vrednotenja zdravljenja z vedolizumabom do danes ne kažejo na povečano tveganje za razvoj malignih obolenj, vendar pa je bilo število malignih obolenj majhno, dolgotrajna izpostavljenost pa omejena.
Based on plausible mechanism and available number of spontaneous reports of herpes zoster, the PRAC concluded that the product information should be updated with herpes zoster as a new adverse drug reaction with frequency uncommon.
Na osnovi verjetnega mehanizma in razpoložljivega števila spontanih poročil o herpesu zostru je odbor PRAC sklenil, da je treba podatke o zdravilu posodobiti s herpesom zostrom kot novo neželeno reakcijo na zdravilo z občasno pogostnostjo.
No individual Preferred Term reported as an IRR occurred at a rate above 1%.
Noben posamezen prednostni izraz, naveden kot reakcija, povezana z infundiranjem, ni bil pogostejši od 1 %.
2 weeks after Treatment 1
2 tedna po prvem zdravljenju
• wheezing or difficulty breathing
• sopenje ali težko dihanje,
Population pharmacokinetic analyses indicate that the distribution volume of vedolizumab is approximately 5 litres.
Analize populacijske farmakokinetike kažejo, da je volumen porazdelitve vedolizumaba približno 5 litrov.
Most infusion related reactions were not serious and occurred during the infusion or within the first hour after infusion is completed.
Večina reakcij, povezanih z infundiranjem, ni bila resnih, pojavile pa so se med infundiranjem ali v prvi uri po koncu infundiranja.
The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are expected to prescribe/use Entyvio are provided with a physician pack containing the following:
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo pred prihodom zdravila na trg vsi zdravniki, za katere se pričakuje, da bodo predpisovali/uporabljali zdravilo Entyvio, prejeli paket izobraževalnih gradiv, ki vsebuje naslednje:
• moderately to severely active Crohn's disease.
• zmerno do močno aktivne Crohnove bolezni.
Grounds for the variation to the terms of the Marketing Authorisation(s) On the basis of the scientific conclusions for vedolizumab the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing vedolizumab is unchanged subject to the proposed changes to the product information.
Podlaga za spremembe pogojev dovoljenja (dovoljenj) za promet z zdravilom Na podlagi znanstvenih zaključkov za vedolizumab odbor CHMP meni, da je razmerje med koristjo in tveganjem zdravil(-a), ki vsebuje(-jo) učinkovino vedolizumab nespremenjeno ob upoštevanju predlaganih sprememb v informacijah o zdravilu.
Serum CRP change from baseline to week 6, median (mcg/mL) Overall‡
Sprememba serumskega CRP od izhodišča do 6. tedna, mediana vrednost (μg/ml) Celokupno‡
Solution should be clear or opalescent, colourless to light yellow and free of visible particulates.
Rekonstituirana raztopina mora biti bistra ali opalescentna, brezbarvna do svetlo rumena in brez vidnih trdnih delcev.
Before starting treatment with vedolizumab, patients must be screened for tuberculosis according to the local practice.
Pred uvedbo zdravljenja z vedolizumabom je treba bolnike pregledati na tuberkulozo v skladu z lokalno prakso.
The formation of anti-vedolizumab antibodies is associated with increased clearance of vedolizumab and lower rates of clinical remission.
Nastanek protiteles proti vedolizumabu je povezan s povečanim očistkom vedolizumaba in nižjimi stopnjami klinične remisije.
Vedolizumab belongs to a group of biological medicines called monoclonal antibodies (MAbs).
Vedolizumab spada v skupino bioloških zdravil, imenovanih monoklonska protitelesa (mAb).
6 weeks after Treatment 1
6 tednov po prvem zdravljenju
• moderately to severely active ulcerative colitis
• zmerno do močno aktivnega ulceroznega kolitisa.
Active severe infections such as tuberculosis (TB), sepsis, cytomegalovirus, listeriosis, and opportunistic infections such as Progressive Multifocal Leukoencephalopathy (PML) (see section 4.4).
Hude aktivne okužbe, kot so tuberkuloza (TB), sepsa, okužba s citomegalovirusom in listerioza, ter oportunistične okužbe, kot je progresivna multifokalna levkoencefalopatija (PML) (glejte poglavje 4.4).
This leaflet is available in formats suitable for the blind or partially sighted patient and can be requested from respective local representative of the Marketing Authorisation Holder.
To navodilo za uporabo je na voljo tudi v oblikah, primernih za slepe ali slabovidne, ki jih lahko pridobite pri lokalnem predstavništvu imetnika dovoljenja za promet z zdravilom.
Reconstituted solution in the vial
rekonstituirana raztopina v viali
Long-term animal studies with vedolizumab to assess its carcinogenic potential have not been conducted because pharmacologically responsive models to monoclonal antibodies do not exist.
Dolgoročne študije na živalih, ki bi ovrednotile kancerogeni potencial vedolizumaba, niso bile izvedene, saj farmakološko odzivni modeli za monoklonska protitelesa ne obstajajo.
If you have previously taken natalizumab (a medicine used to treat multiple sclerosis) or rituximab (a medicine used to treat certain types of cancer and rheumatoid arthritis), tell your doctor, who will decide if you can be given Entyvio.
Če ste se predhodno zdravili z natalizumabom (zdravilo za zdravljenje multiple skleroze) ali rituksimabom (zdravilo za zdravljenje nekaterih vrst raka in revmatoidnega artritisa), o tem obvestite svojega zdravnika.
Pharmacotherapeutic group: immunosuppressants, selective immunosuppressants, ATC code: L04AA33
Farmakoterapevtska skupina: Zdravila za zaviranje imunske odzivnosti, zdravila za selektivno zaviranje imunske odzivnosti, oznaka ATC: L04AA33
If you do not respond well enough or are intolerant to these medicines, your doctor may give you Entyvio to reduce the signs and symptoms of your disease.
Če odziv na zdravljenje s temi zdravili ni bil zadosten ali ga niste prenašali, lahko zdravnik za zmanjšanje znakov in simptomov bolezni uvede zdravljenje z zdravilom Entyvio.